114 related articles for article (PubMed ID: 36640215)
21. Long-term clinical, angiographic, and optical coherence tomography findings of Mg-based bioresorbable scaffold in patients with acute coronary syndrome.
Gutiérrez-Barrios A; Gheorghe LL; Camacho Freire S; Silva E; Gómez Menchero A; Francisco Jose MP; Cañadas Pruaño D; Martínez Capoccioni U; Gomez Lara J; Bretones Del Pino T; Calle Perez G
Catheter Cardiovasc Interv; 2021 Jul; 98(1):E69-E77. PubMed ID: 33600069
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Angiographic Outcomes With a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold.
Chevalier B; Abizaid A; Carrié D; Frey N; Lutz M; Weber-Albers J; Dudek D; Weng SC; Akodad M; Anderson J; Stone GW
Circ Cardiovasc Interv; 2019 Jun; 12(6):e007283. PubMed ID: 31177821
[TBL] [Abstract][Full Text] [Related]
23. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
24. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'.
Kočka V; Malý M; Toušek P; Buděšínský T; Lisa L; Prodanov P; Jarkovský J; Widimský P
Eur Heart J; 2014 Mar; 35(12):787-94. PubMed ID: 24419808
[TBL] [Abstract][Full Text] [Related]
25. MAGnesium-based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design.
Brugaletta S; Cequier A; Alfonso F; Iñiguez A; Romaní S; Serra A; Salinas P; Goicolea J; Bordes P; Del Blanco BG; Hernández-Antolín R; Pernigotti A; Gómez-Lara J; Sabaté M
Catheter Cardiovasc Interv; 2019 Jan; 93(1):64-70. PubMed ID: 30196572
[TBL] [Abstract][Full Text] [Related]
26. Drug-Eluting Resorbable Magnesium Scaffold Implantation in ST-Segment Elevation Myocardial Infarction: A Pilot Study.
de Hemptinne Q; Picard F; Briki R; Awada A; Silance PG; Dolatabadi D; Debbas N; Unger P
J Invasive Cardiol; 2018 Jun; 30(6):202-206. PubMed ID: 29656279
[TBL] [Abstract][Full Text] [Related]
27. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
[TBL] [Abstract][Full Text] [Related]
28. A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY-IT study.
Ielasi A; Varricchio A; Campo G; Leoncini M; Cortese B; Vicinelli P; Brugaletta S; di Uccio FS; Latib A; Tespili M
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1129-1138. PubMed ID: 27774758
[TBL] [Abstract][Full Text] [Related]
29. Optical Coherence Tomography- Versus Angiography-Guided Magnesium Bioresorbable Scaffold Implantation in NSTEMI Patients.
Fallesen CO; Antonsen L; Maehara A; Noori M; Hougaard M; Hansen KN; Ellert J; Ahlehoff O; Veien KT; Lassen JF; Junker AB; Hansen HS; Jensen LO
Cardiovasc Revasc Med; 2022 Jul; 40():101-110. PubMed ID: 34949544
[TBL] [Abstract][Full Text] [Related]
30. Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial.
Rai H; Alfonso F; Maeng M; Bradaric C; Wiebe J; Cuesta J; Christiansen EH; Cassese S; Hoppmann P; Colleran R; Harzer F; Bresha J; Nano N; Schneider S; Laugwitz KL; Joner M; Kastrati A; Byrne RA
Int J Cardiovasc Imaging; 2021 Oct; 37(10):2815-2826. PubMed ID: 34420177
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
[TBL] [Abstract][Full Text] [Related]
32. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
33. A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study.
Ielasi A; Campo G; Rapetto C; Varricchio A; Cortese B; Brugaletta S; Geraci S; Vicinelli P; Scotto di Uccio F; Secco GG; Poli A; Nicolini E; Ishida K; Latib A; Tespili M
JACC Cardiovasc Interv; 2017 Sep; 10(18):1855-1864. PubMed ID: 28935077
[TBL] [Abstract][Full Text] [Related]
34. Long-term serial functional evaluation after implantation of the Fantom sirolimus-eluting bioresorbable coronary scaffold.
Saito Y; Cristea E; Bouras G; Abizaid A; Lutz M; Carrié D; Weber-Albers J; Dudek D; Anderson J; Lansky A;
Catheter Cardiovasc Interv; 2021 Feb; 97(3):431-436. PubMed ID: 32077590
[TBL] [Abstract][Full Text] [Related]
35. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
[TBL] [Abstract][Full Text] [Related]
36. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
[TBL] [Abstract][Full Text] [Related]
37. Impact of Absorb bioresorbable scaffold implantation technique on post-procedural quantitative coronary angiographic endpoints in ST-elevation myocardial infarction: a sub-analysis of the BVS STEMI STRATEGY-IT study.
Hioki H; Brugaletta S; Ishida K; Campo G; Biscaglia S; Ortega-Paz L; Cortese B; Varricchio A; Latib A; Sabaté M; Tespili M; Ielasi A
EuroIntervention; 2019 May; 15(1):108-115. PubMed ID: 30398966
[TBL] [Abstract][Full Text] [Related]
38. One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions.
Wang XZ; Zhang YJ; Fu GS; Jing QM; Xu B; Han YL
Catheter Cardiovasc Interv; 2018 Feb; 91(S1):617-622. PubMed ID: 29392879
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction.
de Hemptinne Q; Picard F; Ly HQ; Ibrahim R; Asgar AW; de Guise P; Doucet S; Dorval JF; Marquis-Gravel G; Levi M; L-L'allier P; Tanguay JF
Acta Cardiol; 2018 Jun; 73(3):276-281. PubMed ID: 28954592
[TBL] [Abstract][Full Text] [Related]
40. Everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stent in primary percutaneous coronary intervention of ST-segment elevation myocardial infarction: a randomized controlled trial.
Eriksen E; Neghabat O; Saeed S; Herstad J; Nordrehaug JE; Tuseth V; Holm NR; Holck EN; Sejr-Hansen M; Maule CF; Barkholt TØ; Andreasen LN; Christiansen EH; Bleie Ø
Coron Artery Dis; 2023 Jan; 34(1):1-10. PubMed ID: 36484214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
